Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $105,500.00 in StockDefense World · 6 days ago
Aquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating UpgradeSeeking Alpha · Oct 16, 2026
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027GlobeNewsWire · Oct 15, 2026
Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock DropPRNewsWire · Oct 7, 2026
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard DalyGlobeNewsWire · Sep 29, 2026
Aquestive Therapeutics, Inc. $AQST Shares Sold by Squarepoint Ops LLCDefense World · Sep 24, 2026Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.11 | -$0.18 | Miss |
| May 13, 2026 | -$0.14 | -$0.07 | Beat |
| Mar 4, 2026 | -$0.13 | -$0.26 | Miss |
| Nov 5, 2025 | -$0.11 | -$0.14 | Miss |
| Aug 11, 2025 | -$0.18 | -$0.14 | Beat |
| May 12, 2025 | -$0.17 | -$0.24 | Miss |